Collaboration between cardiologist and clinical pharmacist on prescription quality: What is the potential clinical impact for cardiology patients?
Acute Coronary Syndrome
/ drug therapy
Adult
Angiotensin-Converting Enzyme Inhibitors
/ therapeutic use
Cardiologists
/ statistics & numerical data
Drug Prescriptions
/ statistics & numerical data
Female
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors
/ therapeutic use
Male
Medication Errors
/ prevention & control
Middle Aged
Pharmacists
/ statistics & numerical data
Pharmacy Service, Hospital
Prospective Studies
Journal
International journal of clinical practice
ISSN: 1742-1241
Titre abrégé: Int J Clin Pract
Pays: India
ID NLM: 9712381
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
received:
15
12
2019
revised:
15
04
2020
accepted:
05
05
2020
pubmed:
28
5
2020
medline:
22
1
2021
entrez:
28
5
2020
Statut:
ppublish
Résumé
The aim of this study was to determine the effect of pharmacists' interventions (PI) on the potential clinical impact of medication errors, including the lack of therapeutic optimisation of patients with cardiologic diseases, such as heart failure and acute coronary syndrome). This was an observational, prospective study conducted in the cardiology department of a French university hospital centre for a duration of 9 months. All prescriptions were analysed and PI were registered for clinical rating by pharmacists and cardiologist. A total of 532 PI cases were recorded in 339 patients, with a mean of 1.57 (±1.04) PI. The PI acceptance rate was 98.1%. "Dose adjustment" and "introduction therapy" were the most common interventions and represented 38.0% and 32.9%, respectively, of all PI. Statins were the most frequently involved drugs (18.1%), followed by ACE (Angiotensin Converting Enzyme) inhibitors (10.9%) and antiplatelet agents (9.3%). Moreover, 13.8% of PI potentially avoided a severe or very severe clinical impact (n = 71) and 38.6% had a significant impact altering the quality of life (n = 198). There was no significant difference between the average score performed by the clinical pharmacist included in the cardiology team and the one obtained by the cardiologist (P = .797). In contrast, a significant difference was observed for the average score established by the pharmacist localised in central pharmacy versus the rating of the cardiologist (P < .001). The collaboration between clinical pharmacists and cardiologists in the medical units seems to be beneficial to the quality of prescriptions, including the implementation of recommendations. The good rate of PI acceptance and the similar rating with the cardiologist show that there is a change in perspective of the pharmacist, being closer to the clinical reality.
Substances chimiques
Angiotensin-Converting Enzyme Inhibitors
0
Hydroxymethylglutaryl-CoA Reductase Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13531Informations de copyright
© 2020 John Wiley & Sons Ltd.
Références
Walsh EK, Hansen CR, Sahm LJ, et al. Economic impact of medication error: a systematic review. Pharmacoepidemiol Drug Saf. 2017;26:481-497.
Ordonnance n° 2016-1729 du 15 décembre 2016 relative aux pharmacies à usage intérieur.
Rose AJ, Fischer SH, Paasche-Orlow MK. Beyond medication reconciliation: the correct medication list. JAMA. 2017;317:2057-2058.
Renaudin P, Baumstarck K, Daumas A, et al. Impact of a pharmacist-led medication review on hospital readmission in a pediatric and elderly population: study protocol for a randomized open-label controlled trial. Trials. 2017;18:65.
Breuker C, Abraham O, di Trapanie L, et al. Patients with diabetes are at high risk of serious medication errors at hospital: interest of clinical pharmacist intervention to improve healthcare. Eur J Intern Med. 2017;38:38-45.
De Oliveira GS, Castro-Alves LJ, Kendall MC, McCarthy R. Effectiveness of pharmacist intervention to reduce medication errors and health-care resources utilization after transitions of care: a meta-analysis of randomized controlled trials. J Patient Saf. 2017.
Roblek T, Deticek A, Leskovar B, et al. Clinical-pharmacist intervention reduces clinically relevant drug-drug interactions in patients with heart failure: a randomized, double-blind, controlled trial. Int J Cardiol. 2016;203:647-652.
Hohl CM, Partovi N, Ghement I, et al. Impact of early in-hospital medication review by clinical pharmacists on health services utilization. PLoS ONE. 2017;12:e0170495.
Magalhães GF, Santos GBNdC, Rosa MB, Noblat LdACB. Medication reconciliation in patients hospitalized in a cardiology unit. PLoS ONE. 2014;9:e115491.
Eggink RN, Lenderink AW, Widdershoven JWMG, van den Bemt PMLA. The effect of a clinical pharmacist discharge service on medication discrepancies in patients with heart failure. Pharm World Sci. 2010;32:759-766.
Jackevicius CA, de Leon NK, Lu L, et al. Impact of a multidisciplinary heart failure post-hospitalization program on heart failure readmission rates. Ann Pharmacother. 2015;49:1189-1196.
López Cabezas C, Falces Salvador C, Cubí Quadrada D, et al. Randomized clinical trial of a postdischarge pharmaceutical care program vs regular follow-up in patients with heart failure. Farm Hosp. 2006;30:328-342.
Wiggins BS, Rodgers JE, DiDomenico RJ, Cook AM, Page RL. Discharge counseling for patients with heart failure or myocardial infarction: a best practices model developed by members of the American College of Clinical Pharmacy’s Cardiology Practice and Research Network based on the Hospital to Home (H2H) Initiative. Pharmacotherapy. 2013;33:558-580.
Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18:891-975.
Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39:119-177.
Breuker C, Macioce V, Mura T, et al. Medication errors at hospital admission and discharge: risk factors and impact of medication reconciliation process to improve healthcare. J Patient Saf. 2017.
Al-Baghdadi H, Koca Al-Baghdadi Ç, Abdi A, et al. Introducing clinical pharmacy services to cardiovascular clinics at a university hospital in Northern Cyprus. Int J Clin Pharm. 2017;39:1185-1193.
Ali MAS, Lobos CM, Abdelmegid MA-KF, El-Sayed AM. The frequency and nature of medication errors in hospitalized patients with acute coronary syndrome. Int J Clin Pharm. 2017;39:542-550.
Hassan Y, Kassab Y, Abd Aziz N, Akram H, Ismail O. The impact of pharmacist-initiated interventions in improving acute coronary syndrome secondary prevention pharmacotherapy prescribing upon discharge. J Clin Pharm Ther. 2013;38:97-100.
Cohen Solal A, Leurs I, Assyag P, et al. Optimization of heart FailUre medical treatment after hospital discharge according to left ventricUlaR Ejection fraction. Arch Cardiovasc Dis. 2012;105:355-365.
Haas S, ten Cate H, Accetta G, et al. Quality of Vitamin K antagonist control and 1-year outcomes in patients with atrial fibrillation: a global perspective from the GARFIELD-AF Registry. PLoS ONE. 2016;11:e0164076.
Mayyas F, Ibrahim K, Alzoubi KH. Awareness of physicians and pharmacists of aldosterone antagonists in heart failure and myocardial infarction in Jordan. Pharm Pract. 2017;15:994.
Renaudin P, Coste A, Audurier Y, et al. Clinical, economic, and organizational impact of the clinical pharmacist in an orthopedic and trauma surgery department. J Patient Saf. 2018.